Previous close | 16.67 |
Open | 17.00 |
Bid | 17.10 x 700 |
Ask | 17.13 x 1400 |
Day's range | 16.82 - 17.81 |
52-week range | 3.53 - 23.86 |
Volume | |
Avg. volume | 17,118,998 |
Market cap | 2.52B |
Beta (5Y monthly) | 1.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.05 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 21.40 |
Novavax stock has pulled back after hitting a nearly two-year high earlier this month. Is NVAX stock a buy right now?
Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.
Here is how Boston Scientific (BSX) and Novavax (NVAX) have performed compared to their sector so far this year.